Jane Street Group, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.33 - $1.39 $93,217 - $392,644	282,478 New	282,478 $358,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $0.72 $12,115 - $17,446	-24,231 Reduced 38.33%	38,984 $20,000
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $54,997 - $85,972	63,215 New	63,215 $46,000
Q2 2022 Aug 16, 2022	SELL	$0.86 - $2.06 $54,477 - $130,492	-63,346 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$1.83 - $3.02 $33,930 - $55,993	18,541 Added 41.38%	63,346 $130,000
Q4 2021 Feb 15, 2022	SELL	$2.88 - $4.3 $86,051 - $128,479	-29,879 Reduced 40.01%	44,805 $129,000
Q3 2021 Nov 16, 2021	BUY	$3.72 - $5.35 $182,968 - $263,139	49,185 Added 192.89%	74,684 $316,000
Q2 2021 Aug 16, 2021	SELL	$3.83 - $5.98 $18,889 - $29,493	-4,932 Reduced 16.21%	25,499 $136,000
Q1 2021 May 18, 2021	BUY	$3.33 - $8.76 $101,335 - $266,575	30,431 New	30,431 $142,000
Q3 2020 Nov 17, 2020	SELL	$3.23 - $4.3 $446,208 - $594,023	-138,145 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$3.31 - $6.54 $457,259 - $903,468	138,145 New	138,145 $466,000
Q4 2019 Feb 14, 2020	SELL	$5.61 - $8.57 $63,684 - $97,286	-11,352 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$7.56 - $15.44 $50,296 - $102,722	-6,653 Reduced 36.95%	11,352 $86,000
Q2 2019 Aug 15, 2019	BUY	$5.4 - $15.5 $97,227 - $279,077	18,005 New	18,005 $244,000
Q1 2019 May 16, 2019	SELL	$3.6 - $6.22 $44,161 - $76,300	-12,267 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$2.89 - $7.91 $67,302 - $184,208	-23,288 Reduced 65.5%	12,267 $36,000
Q3 2018 Nov 14, 2018	BUY	$5.59 - $10.45 $61,305 - $114,605	10,967 Added 44.6%	35,555 $290,000
Q2 2018 Aug 15, 2018	BUY	$7.98 - $12.39 $196,212 - $304,645	24,588 New	24,588 $239,000

Others Institutions Holding ZYNE

# of Institutions

Shares Held

774K

Call Options Held

Put Options Held

View Full List

About Zynerba Pharmaceuticals, Inc.

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

More about ZYNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account